StockMacro
Company, fund or insider

Help

Menu

Atara Biotherapeutics

$6.33 -34% in 6 monthsMarket cap $64.5M

ATRA on XNAS, Health Care, Atara Biotherapeutics, Inc, job postings

Measures activity, not value. Not investment advice.

Revenue fell 97% to $4M while insiders bought $1M of stock and shares are down 52% in a year.

  • BadNet loss $14.6M over 12 months against cash of $9.9M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
10
Website
atarabio.com
Listed
Nasdaq, US
Last results
10 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $1.2M, net loss $2.2M.
Quarter to 31 Dec 2021: revenue –, net income -$93.3MQuarter to 31 Mar 2022: revenue $7.3M, net income -$88.1MQuarter to 31 Mar 2022: revenue $7.3M, net income -$88.1MQuarter to 30 Jun 2022: revenue $51.6M, net income $18.5MQuarter to 30 Jun 2022: revenue $51.6M, net income $18.5MQuarter to 30 Sep 2022: revenue $4.5M, net income -$84.1MQuarter to 30 Sep 2022: revenue $4.5M, net income -$84.1MQuarter to 31 Dec 2022: revenue –, net income -$74.6MQuarter to 31 Mar 2023: revenue $1.2M, net income -$74.8MQuarter to 31 Mar 2023: revenue $1.2M, net income -$74.8MQuarter to 30 Jun 2023: revenue $957K, net income -$71.1MQuarter to 30 Jun 2023: revenue $957K, net income -$71.1MQuarter to 30 Sep 2023: revenue $2.1M, net income -$69.8MQuarter to 30 Sep 2023: revenue $2.1M, net income -$69.8MQuarter to 31 Dec 2023: revenue $4.3M, net income -$60.5MQuarter to 31 Dec 2023: revenue $4.3M, net income -$60.5MQuarter to 31 Mar 2024: revenue $27.4M, net income -$31.8MQuarter to 31 Mar 2024: revenue $27.4M, net income -$31.8MQuarter to 30 Jun 2024: revenue $28.6M, net income -$19.0MQuarter to 30 Jun 2024: revenue $28.6M, net income -$19.0MQuarter to 30 Sep 2024: revenue $40.2M, net income -$21.9MQuarter to 30 Sep 2024: revenue $40.2M, net income -$21.9MQuarter to 31 Dec 2024: revenue $32.8M, net income -$12.7MQuarter to 31 Dec 2024: revenue $32.8M, net income -$12.7MQuarter to 31 Mar 2025: revenue $98.1M, net income $38.0MQuarter to 31 Mar 2025: revenue $98.1M, net income $38.0MQuarter to 30 Jun 2025: revenue $17.6M, net income $2.4MQuarter to 30 Jun 2025: revenue $17.6M, net income $2.4MQuarter to 30 Sep 2025: revenue $3.5M, net income -$4.3MQuarter to 30 Sep 2025: revenue $3.5M, net income -$4.3MQuarter to 31 Dec 2025: revenue –, net income -$3.4MQuarter to 31 Mar 2026: revenue $516K, net income -$4.1MQuarter to 31 Mar 2026: revenue $516K, net income -$4.1MQuarter to 30 Jun 2026: revenue $630K, net income -$4.8MQuarter to 30 Jun 2026: revenue $630K, net income -$4.8MQuarter to 30 Sep 2026: revenue $1.2M, net income -$2.2MQuarter to 30 Sep 2026: revenue $1.2M, net income -$2.2M
31 Dec 2021RevenueNet incomeNet losstallest bar $98.1M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$1.2M-$2.2M
30 Jun 2026$630K-$4.8M
31 Mar 2026$516K-$4.1M
31 Dec 2025–-$3.4M
30 Sep 2025$3.5M-$4.3M
30 Jun 2025$17.6M$2.4M
31 Mar 2025$98.1M$38.0M
31 Dec 2024$32.8M-$12.7M
30 Sep 2024$40.2M-$21.9M
30 Jun 2024$28.6M-$19.0M
31 Mar 2024$27.4M-$31.8M
31 Dec 2023$4.3M-$60.5M
30 Sep 2023$2.1M-$69.8M
30 Jun 2023$957K-$71.1M
31 Mar 2023$1.2M-$74.8M
31 Dec 2022–-$74.6M
30 Sep 2022$4.5M-$84.1M
30 Jun 2022$51.6M$18.5M
31 Mar 2022$7.3M-$88.1M
31 Dec 2021–-$93.3M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $4.0M $151.9M
Revenue growthRevenue of the last 12 months compared with the 12 months before. -97% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$14.6M $23.4M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$1.12 $3.64
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -344% 17.3% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -369% 15.4% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – -$69.8M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $9.9M $13.7M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 16.3 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Atara BiotherapeuticsATRA (this company) $64.5Mloss16.3-97%-369%
Tenaya TherapeuticsTNYA $65.3Mloss–––
Neumora TherapeuticsNMRA $63.0Mloss–––
Cardiff OncologyCRDF $66.3Mloss119+12%–
Champions OncologyCSBR $60.4Mloss1.00+6.7%-1.8%
Coherus OncologyCHRS $57.1Mloss1.1-36%-253%

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$920K

bought $1.0M, sold $80K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-2.8%

35 13F filers vs 36

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

45%

4.6M shares held by 13F filers (30 Sep 2026) of 10.2M outstanding (6 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

2.9%

297K shares sold short (30 Oct 2026) of 10.2M outstanding (6 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

13.4

297K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-15%

350K shares sold short in the report before, 297K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

53%

53% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 47%

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$20K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

14

14 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

14 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.

Price $6.33 on 20 Nov 2026, -52% over 12 months (12-month range $4.18 to $18.09)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders bought a net $1.9M in the last 12 months (the 12 months before: $663K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months.
Revenue per quarter. Revenue $1.2M in the latest quarter, -65% on a year earlier.
Capital spending per quarter. Capital spending $0 in the latest quarter, -100% on a year earlier.
Institutional holders (13F filers). 35 13F filers reported holding it in the latest 13F quarter, -2.8% on a year earlier.
Lobbying spend. Lobbying spend: $20K published in the last 12 months, -67% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
26 Jun 20268-K and other filingsDirector or officer change
12 Jun 20268-K and other filingsDirector or officer change
12 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 May 20268-K and other filingsDelisting notice or listing transfer
3 Apr 2026Lobbying filingnew lobbying registration (JEFFREY J. KIMBELL & ASSOCIATES, INC.)
3 Feb 2026Sharp changeShort interest spike: short interest spike, 1.0M vs usual 267K (2026-01-15); 1.9x the same period a year earlier
6 Oct 20258-K and other filingsRestructuring costs announced
3 Sep 20258-K and other filingsDirector or officer change
3 Sep 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Jul 2025Lobbying filinglobbying engagement terminated (KING & SPALDING LLP)
20 May 2025Sharp changeQuarterly revenue change: quarterly revenue change, 98.1M vs usual 15.8M (2025-03-31); 3.6x the same period a year earlier
15 May 20258-K and other filingsDirector or officer change
12 May 20258-K and other filingsRestructuring costs announced
31 Mar 20258-K and other filingsDirector or officer change
31 Mar 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Mar 2025Sharp changeQuarterly revenue change: quarterly revenue change, 32.8M vs usual 4.4M (2024-12-31); 7.7x the same period a year earlier
3 Mar 20258-K and other filingsRestructuring costs announced
27 Jan 20258-K and other filingsRestructuring costs announced
19 Nov 2024Sharp changeQuarterly revenue change: quarterly revenue change, 40.2M vs usual 4.4M (2024-09-30); 18.8x the same period a year earlier
12 Nov 20248-K and other filingsDirector or officer change
15 Oct 20248-K and other filingsDirector or officer change
3 Sep 20248-K and other filingsDirector or officer change
13 Aug 2024Sharp changeQuarterly revenue change: quarterly revenue change, 28.6M vs usual 4.4M (2024-06-30); 29.9x the same period a year earlier
12 Aug 20248-K and other filingsDirector or officer change
12 Aug 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 May 2024Sharp changeQuarterly revenue change: quarterly revenue change, 27.4M vs usual 4.3M (2024-03-31); 22.3x the same period a year earlier
29 Mar 20248-K and other filingsDirector or officer change
23 Feb 20248-K and other filingsDirector or officer change
9 Jan 20248-K and other filingsDelisting notice or listing transfer
8 Jan 20248-K and other filingsRestructuring costs announced
8 Jan 20248-K and other filingsDirector or officer change
8 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Nov 2023Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 195K)
1 Nov 20238-K and other filingsRestructuring costs announced
9 Jun 20238-K and other filingsDirector or officer change
5 Jun 20238-K and other filingsDirector or officer change
16 May 2023Sharp changeShort interest spike: short interest spike, 17.8M vs usual 12.1M (2023-04-28); 1.5x the same period a year earlier
12 May 20238-K and other filingsDirector or officer change
8 May 20238-K and other filingsDirector or officer change
2 May 2023Sharp changeShort interest spike: short interest spike, 19.2M vs usual 12.0M (2023-04-14); 1.7x the same period a year earlier
18 Apr 2023Sharp changeShort interest spike: short interest spike, 20.0M vs usual 11.9M (2023-03-31); 2.1x the same period a year earlier
31 Mar 20238-K and other filingsDirector or officer change
28 Mar 2023Sharp changeShort interest spike: short interest spike, 16.7M vs usual 11.8M (2023-03-15); 1.9x the same period a year earlier
8 Feb 20238-K and other filingsDirector or officer change
19 Dec 20228-K and other filingsDirector or officer change
19 Dec 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Nov 2022Sharp changeMany funds opening a new position: many funds opening a new position, 38 vs usual 17.50 (2022-09-30); 2.5x the same period a year earlier
8 Aug 20228-K and other filingsRestructuring costs announced
8 Aug 20228-K and other filingsDirector or officer change
8 Aug 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 May 20228-K and other filingsA major agreement ended
4 Apr 20228-K and other filingsCompleted an acquisition or asset sale
26 Jan 20228-K and other filingsDirector or officer change
26 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$90K published
Month from 1 Jan 2022: -$80K published
Month from 1 Feb 2022: -$116K published
Month from 1 Mar 2022: -$171K published
Month from 1 May 2022: -$141K published
Month from 1 Jun 2022: -$135K published
Month from 1 Aug 2022: -$143K published
Month from 1 Nov 2022: -$134K published
Month from 1 Feb 2023: -$14K published
Month from 1 Mar 2023: -$116K published
Month from 1 May 2023: -$133K published
Month from 1 Jun 2023: -$24K published
Month from 1 Aug 2023: -$121K published
Month from 1 Nov 2023: $170K published
Month from 1 Mar 2024: -$40K published
Month from 1 May 2024: -$131K published
Month from 1 Aug 2024: -$53K published
Month from 1 Nov 2024: -$45K published
Month from 1 Mar 2025: -$39K published
Month from 1 May 2025: -$37K published
Month from 1 Jul 2025: $186K published
Month from 1 Aug 2025: $615K published
Month from 1 Nov 2025: -$62K published
Month from 1 Jan 2026: -$489K published
Month from 1 Mar 2026: -$26K published
Month from 1 May 2026: $1.5M published
Month from 1 Aug 2026: -$41K published
Month from 1 Sep 2026: $1.0M published
Month from 1 Nov 2026: -$39K published
H-1B/E-3 applications certified
Quarter from 1 Apr 2022: 3 published
Quarter from 1 Jul 2022: 3 published
Quarter from 1 Oct 2022: 2 published
Quarter from 1 Jul 2023: 3 published
Quarter from 1 Oct 2023: 3 published
Revenue per quarter
Quarter ended 31 Mar 2022: $7.3M; public on 9 May 2023
Quarter ended 30 Jun 2022: $51.6M; public on 9 Aug 2023
Quarter ended 30 Sep 2022: $4.5M; public on 2 Nov 2023
Quarter ended 31 Mar 2023: $1.2M, -83% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $957K, -98% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $2.1M, -52% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $4.3M; public on 29 Mar 2024
Quarter ended 31 Mar 2024: $27.4M, +2131% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $28.6M, +2893% on a year earlier; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $40.2M, +1780% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $32.8M, +670% on a year earlier; public on 8 Mar 2025
Quarter ended 31 Mar 2025: $98.1M, +259% on a year earlier; public on 16 May 2025
Quarter ended 30 Jun 2025: $17.6M, -39% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $3.5M, -91% on a year earlier; public on 13 Nov 2025
Quarter ended 31 Mar 2026: $516K, -99% on a year earlier; public on 13 May 2026
Quarter ended 30 Jun 2026: $630K, -96% on a year earlier; public on 13 Aug 2026
Quarter ended 30 Sep 2026: $1.2M, -65% on a year earlier; public on 11 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $2.5M, +310% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $2.6M, +19% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $1.4M, -31% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $132K, -97% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Mar 2023: $399K, -85% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $499K, -65% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $281K, +113% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $44K; public on 29 Mar 2024
Quarter ended 31 Mar 2024: $127K, -68% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $29K, -94% on a year earlier; public on 13 Aug 2024
Quarter ended 31 Dec 2024: $90K, +105% on a year earlier; public on 8 Mar 2025
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 16 May 2025
Quarter ended 30 Jun 2025: $0, -100% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $0; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $0, -100% on a year earlier; public on 17 Mar 2026
Institutional holders (13F filers)
31 Dec 2021 report: 125; public on 14 Feb 2022
31 Mar 2022 report: 137; public on 16 May 2022
30 Jun 2022 report: 125; public on 15 Aug 2022
30 Sep 2022 report: 146; public on 14 Nov 2022
31 Dec 2022 report: 130; public on 14 Feb 2023
31 Mar 2023 report: 117; public on 15 May 2023
30 Jun 2023 report: 108; public on 14 Aug 2023
30 Sep 2023 report: 100; public on 14 Nov 2023
31 Dec 2023 report: 84; public on 14 Feb 2024
31 Mar 2024 report: 79; public on 15 May 2024
30 Jun 2024 report: 46; public on 14 Aug 2024
30 Sep 2024 report: 34; public on 14 Nov 2024
31 Dec 2024 report: 43; public on 14 Feb 2025
31 Mar 2025 report: 35; public on 15 May 2025
30 Jun 2025 report: 31; public on 14 Aug 2025
30 Sep 2025 report: 36; public on 14 Nov 2025
31 Dec 2025 report: 40; public on 17 Feb 2026
31 Mar 2026 report: 33; public on 15 May 2026
30 Jun 2026 report: 36; public on 14 Aug 2026
30 Sep 2026 report: 35; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $60K published
Quarter from 1 Apr 2022: $60K published
Quarter from 1 Jul 2022: $60K published
Quarter from 1 Oct 2022: $60K published
Quarter from 1 Jan 2023: $60K published
Quarter from 1 Apr 2023: $60K published
Quarter from 1 Jul 2023: $60K published
Quarter from 1 Oct 2023: $60K published
Quarter from 1 Jan 2024: $60K published
Quarter from 1 Apr 2024: $30K published
Quarter from 1 Jul 2024: $30K published
Quarter from 1 Oct 2024: $30K published
Quarter from 1 Jan 2025: $30K published
Quarter from 1 Apr 2025: $30K published
Quarter from 1 Jul 2026: $10K published
Quarter from 1 Oct 2026: $10K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is lobbying spend reported (quarter) at $10K (30 Sep 2026), 67% below its normal reading of $30K; higher than 11% of its own history.
  • Insider net buying (open market): Insiders bought a net $1.9M in the last 12 months (the 12 months before: $663K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months.
  • Revenue per quarter: Revenue $1.2M in the latest quarter, -65% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 2 sales, $80K; 1 purchase, $1.0M. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026AnhCo NguyenPresident and CEOSell6,094$6.46$39KForm 4
4 Sep 2026Brian N CherryDirectorBuy104,166$9.60$1.0MForm 4
26 Aug 2026AnhCo NguyenPresident and CEOSell5,062$8.08$41KForm 4
20 May 2026AnhCo NguyenPresident and CEOSell5,241$9.13$48KForm 4
20 May 2026Yanina Grant-HuertaChief Accounting OfficerSell2,414$9.13$22KForm 4
11 May 2026Panacea Innovation Ltd and 1 other10% ownerSell313,446$10.10$3.2MForm 4
11 May 2026EcoR1 Capital, LLC10% ownerBuy507,407$9.35$4.7MForm 4
4 Mar 2026Yanina Grant-HuertaChief Accounting OfficerSell2,104$5.08$11KForm 4

35 institutions reported shares at the end of Q3 2026, 45% of the shares outstanding; 3 opened a position, 4 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
EcoR1 Capital, LLC1.6M15.2%$13.2MNo change
Adage Capital Partners GP, L.L.C.850K8.34%$7.2MNo change
Point72 Asset Management, L.P.678K6.65%$5.8M-10K-1.5%
Redmile Group, LLC637K6.25%$5.4M+195K+44%
Vanguard Capital Management LLC247K2.42%$2.1MNo change
Mackenzie Financial Corp177K1.73%$1.5M-56K-24%
BlackRock, Inc.85K0.84%$725K+847+1.0%
Geode Capital Management, LLC81K0.79%$688K+5,822+7.7%
Vanguard Fiduciary Trust Co51K0.50%$431K+7,667+18%
Staley Capital Advisers Inc50K0.49%$425KNo change

Company events

All 59 company events

In 12 months: 2 major agreements, 2 director or officer changes, 1 delisting notice. Results releases and routine reports are left out.

FiledWhat happenedSource
26 Jun 2026Director or officer change8-K
12 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
1 May 2026Delisting notice or listing transfer8-K
23 Feb 2026Signed a major agreementSame filing: sold shares privately8-K
2 Jan 2026Signed a major agreement8-K
6 Oct 2025Restructuring costs announced8-K
3 Sep 2025Director or officer change8-K
15 May 2025Director or officer change8-K

Reported lobbying spend: $10K in Q3 2026, $10K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
3 Apr 2026NewJeffrey J. Kimbell & Associates, Inc.for Atara Biotherapeutics, Inc.Issues related to regulation of cell therapiesHealth issuesFiling
30 Jun 2025EndedKing & Spalding LLPfor Atara Biotherapeutics, Inc.Not statedFiling
17 Feb 2021NewKing & Spalding LLPfor Atara Biotherapeutics, Inc.Advocacy related to healthcare, FDA, and biotechnologyHealth issuesFiling

The 5 newest of 69 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 5 Sep 2026Insiders record

    Cherry Brian N (director) bought 104,166 shares of ATRA ($999,994) (dated 4 Sep 2026)

  2. 26 Jun 2026Filings record

    Director or officer change

  3. 12 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 12 Jun 2026Filings record

    Director or officer change

  5. 12 May 2026Insiders record

    EcoR1 Capital, LLC (ten percent owner) bought 507,407 shares of ATRA ($4.7M) (dated 11 May 2026)

  6. 1 May 2026Filings record

    Delisting notice or listing transfer

  7. 3 Apr 2026Lobbying record

    ATARA BIOTHERAPEUTICS, INC.: new lobbying registration (JEFFREY J. KIMBELL & ASSOCIATES, INC.)

  8. 28 Jan 2026Short interest and volume change

    had 1.0M shares sold short in the 15 Jan 2026 report, 1.9× the same report last year.

    Same report last year: 548K; its normal report is 267K.

    See the evidence
    This period
    1.0M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    267K
    Typical spread (median absolute deviation)
    104K
    How far from its usual level
    +4.8
    Same report last year
    548K
    History used
    2,939 days
    2025-01-15: 548K2025-01-31: 706K2025-02-14: 675K2025-02-28: 715K2025-03-14: 723K2025-03-31: 667K2025-04-15: 662K2025-04-30: 522K2025-05-15: 413K2025-05-30: 367K2025-06-13: 286K2025-06-30: 267K2025-07-15: 268K2025-07-31: 211K2025-08-15: 196K2025-08-29: 174K2025-09-15: 162K2025-09-30: 150K2025-10-15: 129K2025-10-31: 169K2025-11-14: 177K2025-11-28: 165K2025-12-15: 167K2025-12-31: 169K2026-01-15: 1.0M
    the 15 Jan 2026 report24 earlier reportsnormal: 267K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 6 Oct 2025Filings record

    Restructuring costs announced

  10. 3 Sep 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 3 Sep 2025Filings record

    Director or officer change

  12. 20 Aug 2025Insiders record

    Panacea Innovation Ltd (ten percent owner) and 1 other(s) bought 55,000 shares of ATRA ($670,450) (dated 19 Aug 2025)

  13. 22 Jul 2025Insiders record

    Huang James (director) and 1 other(s) bought 19,335 shares of ATRA ($186,389) (dated 21 Jul 2025)

  14. 21 Jul 2025Lobbying record

    ATARA BIOTHERAPEUTICS, INC.: lobbying engagement terminated (KING & SPALDING LLP) (dated 30 Jun 2025)

  15. 20 May 2025Financials change

    reported revenue of $98.1M for the quarter ended 31 Mar 2025, 3.6× the same quarter last year.

    Same quarter last year: $27.4M; its normal quarter is $15.8M.

    See the evidence
    This period
    $98.1M (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    $15.8M
    Typical spread (median absolute deviation)
    $14.1M
    How far from its usual level
    +3.9
    Same quarter last year
    $27.4M
    History used
    1,096 days
    2023-03-31: $1.2M2023-06-30: $957K2023-09-30: $2.1M2023-12-31: $4.3M2024-03-31: $27.4M2024-06-30: $28.6M2024-09-30: $40.2M2024-12-31: $32.8M2025-03-31: $98.1M
    the quarter ended 31 Mar 20258 earlier quartersnormal: $15.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  16. 15 May 2025Filings record

    Director or officer change

  17. 12 May 2025Filings record

    Restructuring costs announced

  18. 31 Mar 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 31 Mar 2025Filings record

    Director or officer change

  20. 11 Mar 2025Financials change

    reported revenue of $32.8M for the quarter ended 31 Dec 2024, 7.7× the same quarter last year.

    Same quarter last year: $4.3M; its normal quarter is $4.4M.

    See the evidence
    This period
    $32.8M (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $4.4M
    Typical spread (median absolute deviation)
    $3.3M
    How far from its usual level
    +5.9
    Same quarter last year
    $4.3M
    History used
    1,006 days
    2022-09-30: $4.5M2023-03-31: $1.2M2023-06-30: $957K2023-09-30: $2.1M2023-12-31: $4.3M2024-03-31: $27.4M2024-06-30: $28.6M2024-09-30: $40.2M2024-12-31: $32.8M
    the quarter ended 31 Dec 20248 earlier quartersnormal: $4.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  21. 3 Mar 2025Filings record

    Restructuring costs announced

  22. 27 Jan 2025Filings record

    Restructuring costs announced

  23. 19 Nov 2024Financials change

    reported revenue of $40.2M for the quarter ended 30 Sep 2024, 19× the same quarter last year.

    Same quarter last year: $2.1M; its normal quarter is $4.4M.

    See the evidence
    This period
    $40.2M (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    $4.4M
    Typical spread (median absolute deviation)
    $3.3M
    How far from its usual level
    +7.4
    Same quarter last year
    $2.1M
    History used
    914 days
    2022-06-30: $51.6M2022-09-30: $4.5M2023-03-31: $1.2M2023-06-30: $957K2023-09-30: $2.1M2023-12-31: $4.3M2024-03-31: $27.4M2024-06-30: $28.6M2024-09-30: $40.2M
    the quarter ended 30 Sep 20248 earlier quartersnormal: $4.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  24. 12 Nov 2024Filings record

    Director or officer change

  25. 15 Oct 2024Filings record

    Director or officer change

  26. 3 Sep 2024Filings record

    Director or officer change

  27. 13 Aug 2024Financials change

    reported revenue of $28.6M for the quarter ended 30 Jun 2024, 30× the same quarter last year.

    Same quarter last year: $957K; its normal quarter is $4.4M.

    See the evidence
    This period
    $28.6M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $4.4M
    Typical spread (median absolute deviation)
    $3.0M
    How far from its usual level
    +5.4
    Same quarter last year
    $957K
    History used
    822 days
    2022-03-31: $7.3M2022-06-30: $51.6M2022-09-30: $4.5M2023-03-31: $1.2M2023-06-30: $957K2023-09-30: $2.1M2023-12-31: $4.3M2024-03-31: $27.4M2024-06-30: $28.6M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $4.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  28. 12 Aug 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  29. 12 Aug 2024Filings record

    Director or officer change

  30. 14 May 2024Financials change

    reported revenue of $27.4M for the quarter ended 31 Mar 2024, 22× the same quarter last year.

    Same quarter last year: $1.2M; its normal quarter is $4.3M.

    See the evidence
    This period
    $27.4M (the quarter ended 31 Mar 2024)
    Normal quarter (median of 7 earlier)
    $4.3M
    Typical spread (median absolute deviation)
    $3.0M
    How far from its usual level
    +5.2
    Same quarter last year
    $1.2M
    History used
    731 days
    2022-03-31: $7.3M2022-06-30: $51.6M2022-09-30: $4.5M2023-03-31: $1.2M2023-06-30: $957K2023-09-30: $2.1M2023-12-31: $4.3M2024-03-31: $27.4M
    the quarter ended 31 Mar 20247 earlier quartersnormal: $4.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  31. 29 Mar 2024Filings record

    Director or officer change

  32. 23 Feb 2024Filings record

    Director or officer change

  33. 9 Jan 2024Filings record

    Delisting notice or listing transfer

  34. 8 Jan 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 8 Jan 2024Filings record

    Director or officer change

  36. 8 Jan 2024Filings record

    Restructuring costs announced

  37. 16 Nov 2023Insiders change

    had 3 insiders buy $195K of its shares on the open market within 30 days (3 filings).

    Who bought: Dobmeier Eric, Heiden William K, Gallagher Carol Giltner.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $195K
    Window
    17 Oct 2023 to 16 Nov 2023

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  38. 16 Nov 2023Insiders record

    Gallagher Carol Giltner (director) bought 270,000 shares of ATRA ($67,588) (dated 15 Nov 2023)

  39. 15 Nov 2023Insiders record

    HEIDEN WILLIAM K (director) bought 100,000 shares of ATRA ($25,000) (dated 14 Nov 2023)

  40. 15 Nov 2023Insiders record

    DOBMEIER ERIC (director) bought 446,825 shares of ATRA ($102,770) (dated 14 Nov 2023)

Showing the newest 40 of 93 entries; narrow the window or the kind of data to see older ones.

Not listed: 442 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001604464
Ticker
ATRA
Domain
atarabio.com
Employer name
Atara Biotherapeutics, Inc. (1 unverified)
Hq location
CA|THOUSAND OAKS|91320 (1 unverified)
Lobbying client
atara biotherapeutics
Name
Atara Biotherapeutics, Inc, Atara Biotherapeutics Ireland Limited, atra-ex21_1.htm, EX-21.1
Wikidata
Q21874220
  • DOL H-1B labor condition applications and PERM certifications136 data points14 Oct 2019 to 5 May 2025
  • Federal lobbying disclosures (LDA)3 records, 59 data points17 Feb 2021 to 30 Sep 2026
  • SEC Form 13F institutional holdings432 data points31 Dec 2014 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)181 records12 Feb 2016 to 10 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)711 data points31 Dec 2012 to 6 Nov 2026
  • SEC Form 4 insider transactions319 records, 796 data points4 Jan 2016 to 18 Nov 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026